Appendix Table.

Case Scenario Results for Whether Data from Quantitative Assessment Impacted Likelihood to Change or Add a DMARD or Biologic

	Amount of Clinical and Metric Information Provided
Degree of info/Metrics	Limited	Expanded	Complete
Case Detail*	Swollen knee & wrist	MTX, Pred, NSAID, AM stiffness 10″,	MTX/ETN, AM stiffness <15″; Pain in MCPs, Wrist
Quantitative disease activity	none	Patient pain 2/10, TJC 5, SJC 1	TJC5, SJC 1
Laboratory data	none	ESR 32, CRP 1.1 mg/dl	CRP 1.5 mg/dl
Composite Metrics Provided	none	HAQ 0.5	DAS 4.10, CDA 12, SDAI 13 GAS 15
Treatment Changes*,** No DMARD or Biologic Change, %	51	22	16
Non-biologic DMARD Change, %	31	49	47
Biologic Add/Switch, %	19	30	37
Odds Ratio (95% CI) for Any DMARD/Biologic Change	Referent	3.7 (2.8–5.0)	5.5 (4.1–7.5)
		Referent	1.5 (1.1–2.0)

^*case and other treatment options (e.g. joint injection) were abbreviated or truncated for brevity

^**may not sum exactly to 100% due to rounding

Explanation: The referent case scenario (left-most column) provided limited clinical information (a swollen wrist and knee) and no RA disease metrics was likely to be managed with joint injection (41%) [not shown]; 49% of rheumatologists said they would change DMARD or biologics. The second case (middle column) provided additional clinical, laboratory (ESR, CRP) and metrics (HAQ, pain VAS, patient global); rheumatologists were 3.7 (2.8–5.0) times more likely to change or add DMARDs or biologics (78%). With yet more quantitative information, (right-most column), rheumatologists were 1.5 (1.1 – 2.0) fold more likely to change DMARDs/biologics (84%) compared to the expanded case (middle column), and 5.5 times likely to change therapy compared to case with the least information.